RZLT Rezolute, Inc.

Nasdaq rezolutebio.com


$ 8.86 $ -0.18 (-2.03 %)    

Friday, 17-Oct-2025 18:55:47 EDT
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 8.69
$ 8.78
$ 8.60 x 466
$ 9.24 x 151
$ 8.54 - $ 8.97
$ 2.22 - $ 9.72
728,128
na
789.15M
$ 36.21
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 09-17-2025 06-30-2025 10-K
2 05-13-2025 03-31-2025 10-Q
3 02-12-2025 12-31-2024 10-Q
4 11-07-2024 09-30-2024 10-Q
5 09-19-2024 06-30-2024 10-K
6 05-15-2024 03-31-2024 10-Q
7 02-13-2024 12-31-2023 10-Q
8 11-13-2023 09-30-2023 10-Q
9 09-14-2023 06-30-2023 10-K
10 05-11-2023 03-31-2023 10-Q
11 02-10-2023 12-31-2022 10-Q
12 11-09-2022 09-30-2022 10-Q
13 09-15-2022 06-30-2022 10-K
14 05-12-2022 03-31-2022 10-Q
15 02-09-2022 12-31-2021 10-Q
16 11-12-2021 09-30-2021 10-Q
17 09-15-2021 06-30-2021 10-K
18 05-17-2021 03-31-2021 10-Q
19 02-10-2021 12-31-2020 10-Q
20 11-12-2020 09-30-2020 10-Q
21 10-13-2020 06-30-2020 10-K
22 05-14-2020 03-31-2020 10-Q
23 02-12-2020 12-31-2019 10-Q
24 11-14-2019 09-30-2019 10-Q
25 09-10-2019 06-30-2019 10-K
26 05-10-2019 03-31-2019 10-Q
27 02-14-2019 12-31-2018 10-Q
28 12-14-2018 09-30-2018 10-Q
29 10-15-2018 06-30-2018 10-K
30 05-15-2018 03-31-2018 10-Q
31 02-14-2018 12-31-2017 10-Q
32 11-14-2017 09-30-2017 10-Q
33 09-22-2017 06-30-2017 10-K
34 05-15-2017 03-31-2017 10-Q
35 02-02-2017 12-31-2016 10-Q
36 11-14-2016 09-30-2016 10-Q
37 09-28-2016 06-30-2016 10-K
38 05-16-2016 03-31-2016 10-Q
39 02-16-2016 12-31-2015 10-Q
40 11-16-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 guggenheim-reiterates-buy-on-rezolute-maintains-15-price-target

Guggenheim analyst Debjit Chattopadhyay reiterates Rezolute (NASDAQ:RZLT) with a Buy and maintains $15 price target.

 maxim-group-maintains-buy-on-rezolute-raises-price-target-to-20

Maxim Group analyst Jason McCarthy maintains Rezolute (NASDAQ:RZLT) with a Buy and raises the price target from $15 to $20.

 btig-reiterates-buy-on-rezolute-maintains-17-price-target

BTIG analyst Julian Harrison reiterates Rezolute (NASDAQ:RZLT) with a Buy and maintains $17 price target.

 rezolute-q4-eps-026-misses-022-estimate

Rezolute (NASDAQ:RZLT) reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate of $(0.22) by...

 hc-wainwright--co-reiterates-buy-on-rezolute-maintains-14-price-target

HC Wainwright & Co. analyst Douglas Tsao reiterates Rezolute (NASDAQ:RZLT) with a Buy and maintains $14 price target.

 rezolute-files-prospectus-to-resale-of-13m-shares-of-common-stock-by-selling-stockholders

-SEC Filing

 rezolute-to-present-late-breaking-phase-3-data-on-rare-hypoglycemia-treatment-at-endo-2025

Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treati...

 rezolute-q3-eps-027-misses-023-estimate

Rezolute (NASDAQ:RZLT) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.23) by...

 rezolute-fda-grants-breakthrough-therapy-designation-to-investigational-therapy-ersodetug-for-treatment-of-hypoglycemia-caused-by-tumor-hi

Registrational study in patients with tumor hyperinsulinism (HI) expected to commence mid-yearDesignation underscores need for ...

 hc-wainwright--co-reiterates-buy-on-rezolute-maintains-14-price-target

HC Wainwright & Co. analyst Douglas Tsao reiterates Rezolute (NASDAQ:RZLT) with a Buy and maintains $14 price target.

 rezolute-thrilled-with-positive-review-of-genetic-disorder-trial-expects-topline-results-in-december

Rezolute advances HI drug trial after DMC review and secures $90 million in funding through stock offering to support development.

 rezolute-announces-pricing-of-offering-of-90m-at-335-per-share-of-common-stock-and-pre-funded-warrants

NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late...

 rezolute-announces-the-data-monitoring-committees-recommendation-to-continue-phase-3-sunrize-study-as-planned-in-patients-with-congenital-hi-without-an-increase-in-the-study-sample-size

Independent Data Monitoring Committee (the "DMC") recommends continuation of sunRIZE trial as planned with no need to i...

 hc-wainwright--co-reiterates-buy-on-rezolute-maintains-14-price-target

HC Wainwright & Co. analyst Douglas Tsao reiterates Rezolute (NASDAQ:RZLT) with a Buy and maintains $14 price target.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION